17
maart

Enceladus Pharmaceuticals BV announces positive results from a phase 2a study in patients with active ulcerative colitis with Nanocort® Results to be presented on March 17th at ECCO 2016 in Amsterdam Nanocort® is a novel i.v. targeted pegylated liposomal prednisolone product Clear benefit shown in 70% of the patients with 2 administrations 7 out of […]